-
Alphamab Oncology Reports 31.12% Revenue Growth in 2023 with Continued R&D Focus
•
Alphamab Oncology (HKG: 9966), a Chinese biopharmaceutical company, has released its financial performance and business updates for 2023. The company reported revenues of RMB 218.77 million (USD 27.6 million), marking a 31.12% increase year-on-year (YOY). Product sales accounted for RMB 195.55 million (USD 27 million), with a YOY growth of…
-
Alphamab and 3D Medicines License Envafolimab Rights to Glenmark for Multiple Regions
•
Alphamab Oncology (HKG: 9966) and 3D Medicines (HKG: 1244), two Chinese pharmaceutical companies, have announced a licensing agreement with Glenmark Pharmaceuticals Ltd (NSE: GLENMARK). The agreement grants the Indian company exclusive development and commercialization rights to the co-developed drug envafolimab (KN035) in India, Asia Pacific (excluding Singapore, Thailand, Malaysia), Middle…
